Confidence of evidence should be considered in ranking of treatments in the network meta-analysis - Authors' reply
- PMID: 35305750
- DOI: 10.1016/S2215-0366(22)00071-2
Confidence of evidence should be considered in ranking of treatments in the network meta-analysis - Authors' reply
Conflict of interest statement
SL has received honoraria for consultancy, advisory work, or lectures from Angelini, Böhringer Ingelheim, Geodon Richter, Janssen, Johnson & Johnson, Lundbeck, LTS Lohmann, MSD, Otsuka, Recordati, Sanofi-Aventis, Sandoz, Sunovion, TEVA, ROVI, EISAI, and Medichem. IB is the deputy coordinating editor of the Cochrane Schizophrenia Group. AR and SS declare no competing interests.
Comment on
-
Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.Lancet Psychiatry. 2022 Mar;9(3):211-221. doi: 10.1016/S2215-0366(21)00437-5. Epub 2022 Jan 31. Lancet Psychiatry. 2022. PMID: 35093198
-
Confidence of evidence should be considered in ranking of treatments in the network meta-analysis.Lancet Psychiatry. 2022 Apr;9(4):e15. doi: 10.1016/S2215-0366(22)00063-3. Lancet Psychiatry. 2022. PMID: 35305749 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
